BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31372942)

  • 1. Association between neutrophil-lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinoma.
    Zhang Y; Brodin NP; Ohri N; Thibaud S; Kaubisch A; Kinkhabwala M; Garg M; Guha C; Kabarriti R
    Hepatol Int; 2019 Sep; 13(5):609-617. PubMed ID: 31372942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis.
    Yang D; Hanna DL; Usher J; LoCoco J; Chaudhari P; Lenz HJ; Setiawan VW; El-Khoueiry A
    Cancer; 2014 Dec; 120(23):3707-16. PubMed ID: 25081299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States.
    Artinyan A; Mailey B; Sanchez-Luege N; Khalili J; Sun CL; Bhatia S; Wagman LD; Nissen N; Colquhoun SD; Kim J
    Cancer; 2010 Mar; 116(5):1367-77. PubMed ID: 20101732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis of Hispanics in a cohort of patients with hepatocellular carcinoma.
    Aparo S; Goel S; Lin D; Ohri N; Schwartz JM; Lo Y; Kaubisch A
    Cancer; 2014 Dec; 120(23):3683-90. PubMed ID: 25081065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
    Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Bilen MA; El-Rayes BF
    Am J Clin Oncol; 2021 Feb; 44(2):74-81. PubMed ID: 33350681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: A propensity score-based analysis.
    Yang HJ; Guo Z; Yang YT; Jiang JH; Qi YP; Li JJ; Li LQ; Xiang BD
    World J Gastroenterol; 2016 Jun; 22(21):5088-95. PubMed ID: 27275101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
    Park Y; Chang AR
    Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma.
    Scaglione S; Adams W; Caines A; Devlin P; Mittal S; Singal AG; Parikh ND
    Dig Dis Sci; 2020 Jun; 65(6):1669-1678. PubMed ID: 31643036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparities in Breast Cancer Survival by Socioeconomic Status Despite Medicare and Medicaid Insurance.
    Silber JH; Rosenbaum PR; Ross RN; Reiter JG; Niknam BA; Hill AS; Bongiorno DM; Shah SA; Hochman LL; Even-Shoshan O; Fox KR
    Milbank Q; 2018 Dec; 96(4):706-754. PubMed ID: 30537364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
    McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
    Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preablation neutrophil-to-lymphocyte ratio as an independent prognostic factor in locally advanced hepatocellular carcinoma patients following radiofrequency ablation.
    Tan W; Sun W; Li X; Zhao L; Wang C; Zang A; Kong X
    J Cancer Res Ther; 2018 Jan; 14(1):84-89. PubMed ID: 29516965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection.
    Huang GQ; Zhu GQ; Liu YL; Wang LR; Braddock M; Zheng MH; Zhou MT
    Oncotarget; 2016 Feb; 7(5):5429-39. PubMed ID: 26716411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.
    Xiao GQ; Liu C; Liu DL; Yang JY; Yan LN
    World J Gastroenterol; 2013 Dec; 19(45):8398-407. PubMed ID: 24363533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
    Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
    Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans.
    El-Serag HB; Kramer J; Duan Z; Kanwal F
    Am J Gastroenterol; 2014 Sep; 109(9):1427-35. PubMed ID: 25070058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes and racial/ethnic differences in hepatocellular carcinoma risk: the multiethnic cohort.
    Setiawan VW; Hernandez BY; Lu SC; Stram DO; Wilkens LR; Le Marchand L; Henderson BE
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25326644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States.
    Lee YT; Wang JJ; Luu M; Tseng HR; Rich NE; Lu SC; Nissen NN; Noureddin M; Singal AG; Yang JD
    Hepatology; 2021 Sep; 74(3):1384-1394. PubMed ID: 33728665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact.
    Govalan R; Luu M; Lauzon M; Kosari K; Ahn JC; Rich NE; Nissen N; Roberts LR; Singal AG; Yang JD
    Hepatol Commun; 2022 Jan; 6(1):223-236. PubMed ID: 34558830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.